Spark Prices Luxturna at $850 Thousand, Looks to Offer Multiple Financing Plans

January 5, 2018: By Jon Swedien

Spark Therapeutics has priced Luxturna, its breakthrough gene therapy, at $850 thousand, or $425 thousand per eye, the Philadelphia company said in an SEC filing Jan. 3.

Some Wall Street analysts had predicted Luxturna (voretigene neparvovec) would be priced at $1 million. The US FDA approved Luxturna in December for the treatment of retinal dystrophies caused by mutations in the RPE65 gene.

Luxturna is the first FDA-approved gene therapy for a genetic disease, the first and only pharmacologic treatment for an inherited retinal disease, and the first adeno-associated virus (AAV) vector gene therapy approved in the US, according to Spark.
Spark also outlined its plan to offer a trio of financing plans to help make the drug affordable.

One plan is an “outcomes-based rebate arrangement that aligns with longer-term efficacy of Luxturna,” the company said. Spark said it will share risk with certain health insurers by paying rebates if patient outcomes fail to meet a specified threshold in short-term (30 to 90 days) and longer-term (30 months) efficacy measures. Spark has reached an agreement with Harvard Pilgrim to offer this rebate arrangement.

Spark also proposed a contracting model, under which a commercial payer or payer’s specialty pharmacy, rather than the treatment center, would purchase Luxturna. The payer would provide coverage for its members consistent with US FDA labeling, expedite benefits processing, and cap patient out-of-pocket amounts at in-network limits. Separately, the payer would agree with the treatment center on reimbursement that is commensurate with the type of specialized medical care required to deliver Luxturna. Spark would assume all drug in-transit, storage, and handling risks. Spark is working with affiliates of Express Scripts to enable this contracting model.

Spark also said it is in discussions with Centers for Medicare & Medicaid Services (CMS) on an annuity-like model that would spread payments over multiple years, while providing flexibility for greater outcomes-based rebates. Due to current government price reporting requirements, Spark said it is not feasible to offer installment payments or outcomes-based rebates above a certain threshold, but Spark has submitted a proposal to CMS to conduct a demonstration project using this model.

Need Deeper Analysis? Sign up for Market Scope's monthly newsletter to get in-depth coverage of the ophthalmic market, including quarterly procedure volumes based on survey data and meeting coverage from around the world.

Recent Ophthalmic News

Carl Zeiss Meditec Announces Milestone of 1.5 Million SMILE Procedures

Heidelberg Gains US Clearance for OCT Angiography Module

ASCRS Convenes Task Force to Study CyPass Data, Make Recommendations

Bascom Palmer Treats First US Patient in Nightstar’s Trial for X-Linked Retinitis Pigmentosa

First Patient Treated in Allotex’ Trial for Allogenic Refractive Lenticules for Presbyopia

Bausch + Lomb Announces Positive Results for Loteprednol Etabonate Gel

LumiThera Set to Launch Valeda Light Delivery System for Dry AMD

Kodiak Sciences Names Jason Ehrlich, MD, PhD, Chief Medical Officer

Second Sight Receives $1.6 Million Grant from NIH to Support Orion Program

Regeneron to Invest $800 Million in New York Campus

American Women Raise Funds for Nepal Mission to Reduce Corneal Blindness

Ziemer to Add Lenticule Extraction Capabilities to LDV Z8

Stealth BioTherapeutics Raises $100 Million in Support of Elamipretide for Dry AMD

STAAR Gains US Approval of Visian Toric ICL

Sun Pharma, SPARC Announce FDA Approval for Xelpros for Open-Angle Glaucoma, Ocular Hypertension

FDA Will Review Regeneron’s Submission to Expand Eylea’s Labeling to All DR Patients

Alcon Will Locate Headquarters in Switzerland

Kodiak Sciences Files for $100 Million IPO

Iridex Announces $10 Million Public Offering

Oxford BioMedica Expands Capacity with New Facility

Coming soon

2018 Ophthalmic Deals Book: Venture Funding, Commercial Equity, and Business/Technology Sales